Opus Genetics announces participation in key ophthalmology conferences to discuss advancements in gene therapies for inherited retinal diseases.
Quiver AI Summary
Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced its participation in several key conferences in February 2026. The leadership team will engage in discussions at the Collaborative Community on Ophthalmic Innovation in Hong Kong, the Asia-Pacific Academy of Ophthalmology Congress, and the Advanced Therapies Week Conference, where Chief Technology Officer Chris Ernst will speak on viral vector manufacturing. Additionally, Dr. Mark Pennesi will present preliminary results from a clinical study of OPGx-BEST1 gene therapy at the Macula Society Annual Meeting. Opus Genetics, based in Research Triangle Park, NC, is developing a pipeline of therapies targeting various genetic retinal disorders and is also advancing a small-molecule therapy for visual disturbances.
Potential Positives
- Opus Genetics is actively participating in multiple prominent ophthalmology conferences, enhancing its visibility and engagement within the global ophthalmology community.
- The company is presenting preliminary results from its gene therapy clinical studies, indicating progress in its pipeline and attracting interest from key stakeholders in the field.
- The leadership team's involvement in discussions about emerging treatment approaches demonstrates a commitment to innovation and collaboration in the rapidly evolving area of retinal disease treatments.
Potential Negatives
- Company's participation in multiple conferences may highlight a lack of recent significant clinical advancements or results, which could raise questions about its current pipeline progress.
- Dependence on ongoing clinical studies for its lead gene therapy products could pose risks if results are not positive, impacting investor confidence.
- As a clinical-stage company, Opus Genetics faces inherent risks associated with drug development and potential regulatory hurdles, which could affect its future viability.
FAQ
What is Opus Genetics focused on?
Opus Genetics develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.
Which conferences will Opus Genetics attend?
Opus Genetics will participate in conferences like CCOI, APAO, and the Macula Society Annual Meeting in early February 2026.
Who are the key speakers from Opus Genetics?
Chris Ernst will speak at Advanced Therapies Week, and Mark Pennesi will present at the Macula Society Annual Meeting.
What are OPGx-LCA5 and OPGx-BEST1?
OPGx-LCA5 targets LCA5-related mutations, and OPGx-BEST1 is for BEST1-related retinal degeneration in Opus’ gene therapy pipeline.
Where is Opus Genetics located?
Opus Genetics is based in Research Triangle Park, North Carolina.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRD Insider Trading Activity
$IRD insiders have traded $IRD stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $IRD stock by insiders over the last 6 months:
- FIGHTING BLINDNESS RETINAL DEGENERATION FUND FOUNDATION sold 4,000,000 shares for an estimated $8,600,000
- CAM GALLAGHER has made 2 purchases buying 164,000 shares for an estimated $323,693 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IRD Revenue
$IRD had revenues of $3.1M in Q3 2025. This is a decrease of -20.38% from the same period in the prior year.
You can track IRD financials on Quiver Quantitative's IRD stock page.
$IRD Hedge Fund Activity
We have seen 23 institutional investors add shares of $IRD stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 980,872 shares (+73.1%) to their portfolio in Q4 2025, for an estimated $1,971,552
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 954,996 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,575,743
- CREATIVE PLANNING added 128,366 shares (+inf%) to their portfolio in Q3 2025, for an estimated $211,803
- MILLENNIUM MANAGEMENT LLC removed 127,844 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $210,942
- ROYAL BANK OF CANADA removed 127,220 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $209,913
- OPALEYE MANAGEMENT INC. removed 120,000 shares (-9.8%) from their portfolio in Q3 2025, for an estimated $198,000
- CITADEL ADVISORS LLC added 113,416 shares (+inf%) to their portfolio in Q3 2025, for an estimated $187,136
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IRD Analyst Ratings
Wall Street analysts have issued reports on $IRD in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/20/2026
- Piper Sandler issued a "Overweight" rating on 11/25/2025
- Chardan Capital issued a "Buy" rating on 11/13/2025
- Wedbush issued a "Outperform" rating on 10/29/2025
To track analyst ratings and price targets for $IRD, check out Quiver Quantitative's $IRD forecast page.
$IRD Price Targets
Multiple analysts have issued price targets for $IRD recently. We have seen 5 analysts offer price targets for $IRD in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Thomas Shrader from BTIG set a target price of $7.0 on 01/28/2026
- Mayank Mamtani from B. Riley Securities set a target price of $9.0 on 12/10/2025
- Biren Amin from Piper Sandler set a target price of $7.0 on 11/25/2025
- Daniil Gataulin from Chardan Capital set a target price of $9.0 on 11/13/2025
- Yun Zhong from Wedbush set a target price of $8.0 on 10/29/2025
Full Release
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.
Collaborative Community on Ophthalmic Innovation (CCOI)
- Topic: Opus Genetics leadership will participate in discussions focused on emerging treatment approaches and clinical insights in retinal disease.
- Date: February 3-4, 2026
-
Location: Hong Kong
Asia-Pacific Academy of Ophthalmology Congress (APAO)
- Topic: The Company will engage with the global ophthalmology community to discuss advances in gene therapy and evolving strategies for treating inherited retinal disorders.
- Date: February 5-8, 2026
-
Location: Hong Kong
Advanced Therapies Week Conference
- Title: Building scalable viral vector manufacturing models
- Speaker: Chris Ernst, Chief Technology Officer, Opus Genetics
- Date/Time: February 11, 2026, 10:30 – 11:00 AM PT
- Location: San Diego, CA
The Macula Society Annual Meeting
- Title: Preliminary Results from Sentinel Patient in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
- Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, OHSU Casey Eye Institute
- Date/Time: February 27, 2026, 7:15 – 7:20 AM PT
-
Location: San Diego, CA
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com .
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
[email protected]
Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]
Source: Opus Genetics, Inc.
